After more than 70 years of effective clinical use, heparin remains the most common anticoagulant in use and one of the most commonly prescribed drugs to ... inhibition of thrombin may offer ...

Discard unused contents and syringe. Epistaxis Kit: Each epistaxis kit contains 1 vial of Thrombin-JMI, 1 vial of diluent and 1 nasal drug delivery device (refer to Thrombin-JMI Epistaxis Kit ...

Sanofi’s drug is also the first antithrombin-lowering ... leading to an increase in thrombin, an enzyme critical for blood clotting. Qfitlia uses small-interfering RNA technology, which enables ...

Summary: Ximelagatran is the first orally active direct thrombin inhibitor to be tested in Phase III clinical trials. After oral administration, ximelagatran is rapidly converted to its active ...

Four years ago, protein drug developer Zymogenetics in Seattle began developing a recombinant version of the blood-clotting protein thrombin. On 17 January, it received US marketing approval for ...

as well as Boehringer Ingelheim's direct thrombin inhibitor Pradaxa (dabigatran). Lixiana was launched in the UK in July. The drug commands a daily price of £2.10 – roughly in line with the ...

Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for at least 16 days. May affect coagulation parameters (increased thrombin time ...

Whether thrombin generation is attenuated (by FXa ... pharmacological and pharmacokinetic attributes of each individual drug may play a greater role in their clinical use. Perhaps the greatest ...